Krilogy Financial LLC Invests $686,000 in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Krilogy Financial LLC bought a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,504 shares of the company’s stock, valued at approximately $686,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in NTLA. Blue Trust Inc. bought a new position in Intellia Therapeutics in the 4th quarter valued at approximately $26,000. Sandia Investment Management LP bought a new position in Intellia Therapeutics in the 4th quarter valued at approximately $35,000. Jefferies Financial Group Inc. bought a new position in Intellia Therapeutics in the 4th quarter valued at approximately $38,000. ICA Group Wealth Management LLC bought a new position in Intellia Therapeutics in the 4th quarter valued at approximately $62,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Intellia Therapeutics by 95.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company’s stock valued at $72,000 after buying an additional 1,108 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Down 4.3 %

Shares of NTLA stock opened at $24.95 on Thursday. The company has a market cap of $2.40 billion, a price-to-earnings ratio of -4.61 and a beta of 1.77. Intellia Therapeutics, Inc. has a 52 week low of $22.67 and a 52 week high of $47.48. The firm has a 50 day moving average of $27.72 and a 200-day moving average of $28.28.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. The business had revenue of ($1.92) million during the quarter, compared to analyst estimates of $15.10 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. During the same quarter in the previous year, the business posted ($1.40) EPS. Analysts anticipate that Intellia Therapeutics, Inc. will post -5.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on NTLA shares. Wedbush reiterated a “neutral” rating and issued a $29.00 price objective on shares of Intellia Therapeutics in a report on Thursday, February 15th. Wolfe Research initiated coverage on shares of Intellia Therapeutics in a research report on Thursday, February 15th. They set a “peer perform” rating for the company. The Goldman Sachs Group downgraded shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $136.00 to $32.00 in a research report on Friday, February 23rd. Finally, Canaccord Genuity Group increased their target price on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $67.00.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the completion of the sale, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.00% of the stock is currently owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.